292 related articles for article (PubMed ID: 29107835)
21. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
22. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
23. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Shen J; Sun H; Meng Q; Yin Q; Zhang Z; Yu H; Li Y
Mol Pharm; 2014 Oct; 11(10):3342-51. PubMed ID: 24495194
[TBL] [Abstract][Full Text] [Related]
25. Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
Iacobazzi RM; Porcelli L; Lopedota AA; Laquintana V; Lopalco A; Cutrignelli A; Altamura E; Di Fonte R; Azzariti A; Franco M; Denora N
Int J Pharm; 2017 Aug; 528(1-2):485-497. PubMed ID: 28624661
[TBL] [Abstract][Full Text] [Related]
26. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
[TBL] [Abstract][Full Text] [Related]
27. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
30. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional PEG modified DOX loaded mesoporous silica nanoparticle@CuS nanohybrids as photo-thermal agent and thermal-triggered drug release vehicle for hepatocellular carcinoma treatment.
Wu L; Wu M; Zeng Y; Zhang D; Zheng A; Liu X; Liu J
Nanotechnology; 2015 Jan; 26(2):025102. PubMed ID: 25517859
[TBL] [Abstract][Full Text] [Related]
32. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
[TBL] [Abstract][Full Text] [Related]
33. A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery.
Thiyagarajan V; Lin SX; Lee CH; Weng CF
Colloids Surf B Biointerfaces; 2016 May; 141():120-131. PubMed ID: 26851441
[TBL] [Abstract][Full Text] [Related]
34. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
[TBL] [Abstract][Full Text] [Related]
35. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.
Zhao W; Zhang Y; Jiang X; Cui C
Drug Des Devel Ther; 2016; 10():3851-3865. PubMed ID: 27920500
[TBL] [Abstract][Full Text] [Related]
37. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
39. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
Şalva E; Turan SÖ; Eren F; Akbuğa J
Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
[TBL] [Abstract][Full Text] [Related]
40. Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma.
Wang G; Gao X; Gu G; Shao Z; Li M; Wang P; Yang J; Cai X; Li Y
Int J Nanomedicine; 2017; 12():3591-3603. PubMed ID: 28533682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
